Diabetes mellitus among adults with tuberculosis in the USA, 2010–2017

Lori R Armstrong, J Steve Kammerer, Maryam B Haddad

To cite: Armstrong LR, Kammerer JS, Haddad MB. Diabetes mellitus among adults with tuberculosis in the USA, 2010–2017. *BMJ Open Diab Res Care* 2020;**8**:e001275. doi:10.1136/bmjdr-2020-001275

Received 11 February 2020
Revised 16 May 2020
Accepted 2 June 2020

ABSTRACT

Introduction To describe diabetes trends among adults with incident tuberculosis (TB) disease and examine diabetes-associated TB characteristics and patient outcomes in the USA.

Research design and methods We examined all 71 855 persons aged ≥ 20 years with incident TB disease reported to the National Tuberculosis Surveillance System during 2010–2017. We performed multivariable logistic regression, comparing characteristics and outcomes among patients with TB reported to have diabetes and those whose diabetes status was unknown.

Results An overall 18% (n=13 281) of the 71 855 adults with incident TB disease were reported as also having diabetes; the annual proportion increased from 15% in 2010 to 22% in 2017. Among patients aged ≥ 45 years with both TB and diabetes, the adjusted OR for cavitary or sputum smear-positive TB was 1.7 and 1.5, respectively (95% CIs 1.5 to 1.8 and 1.4 to 1.6). Patients with TB and diabetes had 30% greater odds of dying and took longer to achieve negative *Mycobacterium tuberculosis* cultures and complete treatment.

Conclusions The prevalence of reported diabetes among adults with TB disease has increased. Having diabetes as a comorbidity negatively affects patient outcomes. In accordance with national recommendations, all patients aged ≥ 45 years and all younger patients who have risk factors for diabetes should be screened for diabetes at the start of TB treatment.

INTRODUCTION

For persons infected with *Mycobacterium tuberculosis*, having diabetes is thought to triple the risk of developing tuberculosis (TB) disease.¹ Worldwide growth in diabetes prevalence is counteracting many countries' otherwise successful TB control strategies.¹ More advanced, infectious forms of TB disease is associated with lung cavities that are visible on chest radiograph and sputum that is smear positive for acid-fast bacilli.² An international meta-analysis of pulmonary TB's radiologic presentations found that compared with patients without diabetes, those with diabetes had more cavitary lesions.³ Prospective studies of newly diagnosed TB cases in Mexico and China found that compared with patients with TB without diabetes, those with diabetes who had started TB treatment experienced delays in achieving negative sputum

Significance of this study

What is already known about this subject?

- ▶ This is the first national analysis describing diabetes among persons with incident tuberculosis (TB) disease in the USA.

What are the new findings?

- ▶ During 2010–2017, 18% of adult patients with TB in the USA were reported as also having a diabetes diagnosis.
- ▶ Non-US-born patients with TB aged ≥ 45 years were reported as having the highest prevalence of diabetes.
- ▶ Consistent with studies in other parts of the world, patients with TB who also had diabetes had more severe TB presentations (70% greater odds of having cavitary TB and 50% greater odds of smear-positive TB).
- ▶ Patients with TB and diabetes had greater odds of death; among adults who did not die, however, TB treatment completion was $>93\%$.

How might these results change the focus of research or clinical practice?

- ▶ These findings underscore the national recommendation for baseline diabetes screening among all patients with TB aged ≥ 45 years and all younger patients who have risk factors for diabetes.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Correspondence to
Dr Maryam B Haddad;
mhaddad@cdc.gov

smears and cultures for *M. tuberculosis*. They were also more likely to die.^{4 5} This greater risk for death was also the conclusion of an international systematic review and a recent analysis of TB cases in California.^{6 7}

Since 1953, the Centers for Disease Control and Prevention has worked with local and state health departments to collect information about each case of TB disease in the USA. TB incidence has declined since 1993.^{8 9} However, because of increased concern about diabetes' role as a frequent TB comorbidity, the National Tuberculosis Surveillance System (NTSS) added diabetes status to the standardized TB case data collection form in 2009.⁹ This is the first national analysis since the addition of that diabetes variable. We describe diabetes trends among adults with incident TB disease during 2010–2017 and

Figure 1 Diabetes reported as a comorbidity among adults with newly diagnosed tuberculosis (TB) disease, as annual count and proportion of total TB cases, USA, 2010–2017.

examine TB disease characteristics and patient outcomes associated with diabetes.

METHODS

Data source and definitions

We analyzed all verified TB cases reported to NTSS from the 50 US states and District of Columbia for 1 January 2010 to 31 December 2017. We excluded 6535 patients with TB aged <20 years because only 45 of these young people were also reported as having diabetes. We also excluded 13 persons with unknown age, none of whom were reported as having diabetes. During 2010–2017, a total of 71 855 persons aged ≥20 years were reported as having TB disease. Standard NTSS patient-level variables include demographics, clinical characteristics, and social risk factors associated with TB (eg, homelessness and substance use). Nativity was considered US-born if the patient had been born in the USA, a US territory, or abroad to at least one US citizen parent.

The diabetes variable, added in 2009, has been reported by all reporting areas since 2010. NTSS defines diabetes as diagnosis of diabetes mellitus either before or concurrent with the TB diagnosis.⁹ Health department staff completing the NTSS form must verify that the diagnosis

is documented by a healthcare provider, but whether it is type 1 or 2 is not collected. Further, until 2020, NTSS did not collect any diabetes-related laboratory results, nor did it have a variable to indicate that diabetes had been ruled out (ie, anyone without a known diabetes diagnosis was coded for this analysis as having unknown diabetes status). Additional medical comorbidities collected in NTSS include HIV infection, end-stage renal disease, history of organ transplantation, or immunosuppression caused by another medical problem.

Prevalence calculations

For each year during 2010–2017, we determined the annual number and proportion of adults with incident TB who were reported as also having diabetes. To more accurately compare diabetes prevalence across racial/ethnic groups of patients with TB, age-adjusted prevalence for each racial/ethnic group was calculated by using the 2010 US population standard.¹⁰

Statistical analysis

We used logistic regression to assess which characteristics were associated with a reported diabetes diagnosis. Our multivariable model initially included any variables that were significant ($p < 0.05$) on univariate analysis. The referent group was persons with unknown diabetes status, and we separately analyzed those aged 20–44 years and those aged ≥45 years. P values for comparing risk factors with continuous counts (eg, time to sputum conversion and time to treatment completion) were obtained by using the Wilcoxon rank-sum test.

Patient protections

NTSS operates under an Assurance of Confidentiality issued under Sections 306 and 308(d) of the US Public Health Service Act (42 USC 242k and 242m(d)). TB case reports were collected as part of routine public health surveillance; this retrospective analysis using existing and non-identifiable data was not considered research and did not require approval by an institutional review board.

RESULTS

Prevalence of diabetes among patients with TB

Of the 71 855 persons aged ≥20 years who were reported as having TB disease during 2010–2017, 18% were reported as also having a diagnosis of diabetes ($n = 13\,281$). Across the 8-year period, the annual proportion of adults with TB who also had diabetes increased from 15% in 2010 to 22% in 2017, and the annual case count of adults with both conditions increased from 1469 to 1815 (figure 1).

Descriptive results

Non-US-born patients with TB aged ≥45 years had the highest prevalence of diabetes (figure 2). After age adjustment, Native Hawaiian/Other Pacific Islander patients with TB had the highest prevalence of diabetes (37%), followed by Hispanic patients (23%) and non-Hispanic Asians (17%). (Age-adjusted prevalence by race/ethnicity

Figure 2 Age-specific prevalence of diabetes reported as a comorbidity among adults with tuberculosis (TB), by nativity and year, USA, 2010–2017.

Table 1 Characteristics of adults with tuberculosis, by diabetes status, USA, 2010–2017

Characteristic	Diagnosed diabetes n=13281		Diabetes status unknown n=58574		χ^2 P value
	n	%	n	%	
End-stage renal disease	950	7.2	996	1.7	<0.001
HIV infection	258	1.9	4061	6.9	<0.001
History of solid organ transplantation	145	1.1	249	0.4	<0.001
Immunosuppression caused by other medical problem	773	5.8	3024	5.2	0.001
Ages 20–44 years	1947	14.7	27670	47.2	<0.001
Ages 45–64 years	6045	45.5	18307	31.3	<0.001
Age ≥65 years	5289	39.8	12597	21.5	<0.001
Self-reported race/ethnicity					
Hispanic	4465	33.6	15260	26.0	<0.001
Non-Hispanic Asian	5066	38.1	18729	32.0	<0.001
Non-Hispanic black	1942	14.6	13705	23.4	<0.001
Non-Hispanic white	1374	10.3	9333	15.9	<0.001
American Indian/Alaska Native	168	1.3	721	1.2	0.374
Native Hawaiian/Other Pacific Islander	170	1.3	344	0.6	<0.001
Other (unknown, missing, or multiple race)	96	0.7	482	0.8	0.122
Non-US-born	9734	73.3	38989	66.6	<0.001
Female	4690	35.3	22796	38.9	<0.001
Known contact of person with infectious TB	188	1.4	1615	2.8	<0.001
Previous diagnosis of TB disease	615	4.6	3073	5.2	0.001
Previous incomplete treatment of latent TB infection	269	2.0	1758	3.0	<0.001
Anatomic site of TB disease					
Pulmonary only	10172	76.6	39520	67.5	<0.001
Both pulmonary and extrapulmonary	1158	8.7	6095	10.4	<0.001
Extrapulmonary only	1947	14.7	12913	22.0	<0.001
Sputum smear positive for acid-fast bacilli*	6593	58.2	21089	46.2	<0.001
Lung cavity visible on chest radiograph*	3717	32.8	11032	24.2	<0.001
TB resistant to isoniazid†	1050	9.5*	4136	9.2*	0.275
TB resistant to rifampin†	167	1.5*	765	1.7*	0.088
Multidrug-resistant TB (resistant to at least isoniazid and rifampin)†	139	1.3*	637	1.4*	0.069
Homeless within the year before TB diagnosis	514	3.9	3500	6.0	<0.001
Excess alcohol use within the year before TB diagnosis	1189	9.0	7091	12.1	<0.001
Injection drug use within the year before TB diagnosis	143	1.1	940	1.6	<0.001
Non-injection drug use within the year before TB diagnosis	546	4.1	4636	7.9	<0.001
Resident of a correctional facility at time of TB diagnosis	165	1.2	2712	4.6	<0.001
Resident of a long-term care facility at time of TB diagnosis	443	3.3	1106	1.9	<0.001

*Denominators for these proportions are based on the 11 330 adults with diagnosed diabetes and the 45615 adults with unknown diabetes status who had a pulmonary site of TB disease.

†Denominators for these proportions are based on the 11 059 adults with diagnosed diabetes and the 44 749 adults with unknown diabetes status whose *Mycobacterium tuberculosis* culture also underwent drug-susceptibility testing.

TB, tuberculosis.

is not shown in table 1, where the presented proportions are based on diabetes status.)

Approximately half of patients with TB who also had diabetes had pulmonary forms of TB that were smear positive for acid-fast bacilli, and nearly a third had evidence

of cavitary TB on chest radiograph (table 1). Social risk factors for TB, including incarceration at the time of diagnosis, recent homelessness, and recent substance misuse, were less prevalent among patients with TB and diabetes. An exception to this pattern was residence in a

Figure 3 Adjusted odds of having diabetes reported as a comorbidity among adults with tuberculosis (TB), by age group, USA, 2010–2017. LTBI, latent TB infection.

long-term care facility at diagnosis, which was more prevalent among patients with TB who also had diabetes as a comorbidity (table 1).

Multivariable model results

Figure 3 presents the adjusted odds of having diabetes as a comorbidity at the time of TB diagnosis; the ORs are presented in descending order from the strongest positive association to the strongest negative association. All variables included in the two age-based models are shown in figure 3. The adjusted odds of also having diabetes was higher among patients with end-stage renal disease (adjusted OR (aOR) if aged 20–44 years: 6.8; 95% CI 4.9 to 9.5; aOR if aged ≥45 years: 3.3; 95% CI 2.9 to 3.6). Among patients with TB aged 20–44 years, lower odds of diabetes was associated with residence in a correctional facility (aOR 0.3; 95% CI 0.2 to 0.4), HIV infection (aOR 0.4; 95% CI 0.3 to 0.5), and non-US-born nativity (aOR 0.7; 95% CI 0.6 to 0.7). In contrast, non-US-born nativity was positively associated (aOR 1.2; 95% CI 1.1 to 1.3) with diabetes among older patients with TB. Among patients with TB aged 20–44 years with diabetes, the aOR for cavitary or sputum smear-positive TB was 1.4 (95% CI 1.1 to 1.7) and 1.9 (95% CI 1.7 to 2.1), respectively, compared with that of patients in the same age group without a

diabetes diagnosis reported. Among patients with TB aged ≥45 years with diabetes, the aOR for cavitary or sputum smear-positive TB was 1.7 (95% CI 1.5 to 1.8) and 1.5 (95% CI 1.4 to 1.6), respectively, compared with that of patients in the same age group without a diabetes diagnosis reported.

Patient outcomes

Patients with TB who had diabetes as a known comorbidity were more likely to die, either before TB treatment could begin or during treatment (table 2). However, the deceased patients with diabetes had an older age distribution than those with unknown diabetes status (table 2). Even after accounting for this older age distribution and excluding the deaths at time of diagnosis, patients with TB and diabetes had 1.3 (95% CI 1.1 to 1.5) the adjusted odds of death during the monthlong treatment period for TB.

After excluding all deaths, TB treatment completion was >93% for both adults with and without diabetes reported (table 2). However, those with diabetes required slightly more time to attain negative *M. tuberculosis* cultures (median days to sputum conversion: 47 vs 42; $p < 0.001$) and an additional month to complete treatment (median days to complete TB treatment: 249 vs 212; $p < 0.001$).

DISCUSSION

Even as overall TB case counts declined 18% in the USA during 2010–2017,⁸ the prevalence of diabetes as a reported comorbidity among adults with TB disease steadily increased from 15% in 2010 to 22% in 2017. An initial interpretation might be that these findings are not surprising—given the high prevalence of diagnosed and undiagnosed diabetes in the USA—but the age-adjusted prevalence of diabetes during the same period is thought to have stabilized at an estimated 9.4% of the adult US population.¹¹

An important limitation of this analysis is potential misclassification (under-reporting) of diabetes as a comorbidity. The 58574 patients listed in table 1 as ‘diabetes status unknown’ include both adults who had diabetes ruled out and adults who were not evaluated for diabetes. Although this analysis could not discriminate between the two possibilities, that important distinction is part of the NTSS case report form revised in 2020. Diabetes was added to the form in 2009, so one might expect that health departments more systematically ascertained diabetes status toward the end of the 2010–2017 period. In addition, screening for diabetes might have increased after the 2016 recommendation to screen all patients aged ≥45 years at the start of TB treatment.² Nevertheless, a strength of this first national analysis of diabetes among persons newly diagnosed with TB disease is that it is based on 71 855 patients with TB, including 13281 reported to have diabetes as a comorbidity.

Table 2 Outcomes among adults with tuberculosis, by diabetes status, USA, 2010–2015*

Patient outcome	Diagnosed diabetes n=9762		Diabetes status unknown n=45 162		χ^2 P value
	n	%	n	%	
Died before TB treatment could be started*	302	3.1	1081	2.4	<0.001
(Cause of death not documented for these patients)	–	–	–	–	–
Ages 20–44 years	9	0.1	160	14.8	
45–64 years	107	35.4	323	29.9	
≥65 years	186	61.6	598	55.3	
Began TB treatment but died before treatment completion	1052	10.8	2610	5.8	<0.001
TB considered a cause of death†	361	34.3	977	37.4	0.038
Ages 20–44 years	44	4.2	277	10.6	
45–64 years	301	28.6	826	31.6	
≥65 years	707	67.2	1505	57.7	
Did not complete treatment because moved/could not be located/other	378	3.9	1990	4.4	0.009
Did not complete treatment due to adverse drug reaction	23	0.2	137	0.3	0.130
Refused to complete TB treatment	64	0.7	349	0.8	0.112
Reason for not completing treatment not documented	76	0.8	371	0.8	0.334
Completed TB treatment, with all patients with TB as denominator	7867	80.6	38 624	85.5	<0.001
Completed TB treatment, excluding deaths from denominator‡	7867	93.6	38 624	93.1	0.063

*Because of the monthslong duration of TB treatment, outcome data can require up to 2 years after the initial case report; therefore, patients with incident TB disease in 2016 and 2017 were excluded from this table. Had we included them, the proportions of patients who died before TB treatment could be started were similar: 375 (2.8%) among the 13 281 adult patients with TB with diagnosed diabetes and 1303 (2.2%) among the 58 574 with unknown diabetes status during 2010–2017.

†Denominators for these proportions are based on the 1052 adult patients with TB with diagnosed diabetes and the 2610 with unknown diabetes status who began TB treatment but died before achieving treatment completion.

‡Denominators for these proportions are based on the 8408 adults with diagnosed diabetes and the 41 471 adults with unknown diabetes status who began TB treatment and did not die during treatment.
TB, tuberculosis.

Despite this potential misclassification (which would be predicted to bias comparisons toward the null), having diabetes as a comorbidity at time of TB diagnosis appears associated with more severe presentations and poorer outcomes in the USA. Patients with TB who were aged ≥45 years and had diabetes had 70% greater odds of having cavitary TB and 50% greater odds of smear-positive TB. We also found 30% greater odds of dying during treatment. These findings are consistent with previous studies from other parts of the world.^{3–6 12}

In our US analysis, patients with diabetes responded more slowly to TB treatment, as evidenced by a median of 5 more days to attain negative *M. tuberculosis* cultures. TB treatment regimens for persons with diabetes took a median of 37 days longer to complete. But in contrast with the findings of other studies,^{4 6} having diabetes did not appear to impede TB treatment completion, despite more complicated case management features, including end-stage renal disease, postorgan transplantation, and long-term care settings. In fact, after excluding deaths, TB treatment completion was >93% (table 2). And although a 2011–2014 study in Tbilisi, Georgia, found that patients with diabetes were more likely to have drug-resistant TB,¹² our study found that patients with both TB

disease and diabetes in the USA during 2010–2017 were not (table 1).

Our findings underscore the recent national recommendation for baseline diabetes screening among all patients with TB aged ≥45 years and all younger patients with risk factors for diabetes (ie, body mass index >25 kg/m²; first-degree relative with diabetes; Hispanic ethnicity; or African–American, Asian, American Indian/Alaska Native, or Hawaiian Native/Pacific Islander race).² Like other infections, *M. tuberculosis* infection can worsen blood glucose control and complicate the clinical management of diabetes. Further, Harries *et al* have appealed for TB screening among persons with diabetes (ie, bidirectional screening).¹³ Indeed, global concern about the ‘converging epidemics of tuberculosis and diabetes’ has helped draw attention to the synergistic influence each might have on the other.^{14 15}

The progression of untreated latent TB infection (LTBI) causes most of the TB disease in the USA.⁸ In older persons, diabetes and the ageing process itself synergistically reduce levels of interferon gamma, impairing cell-mediated immunity and helping to activate progression of long-standing LTBI.¹⁶ Both TB disease and LTBI in the USA occur primarily among non-US-born persons.^{8 17 18}

Preventing active, infectious forms of TB disease thus requires scaling up of interventions to detect and treat LTBI in this population.¹⁹

The International Diabetes Federation projects that 693 million adults will have diabetes by 2024.²⁰ Our analysis revealed that non-US-born patients with TB aged ≥45 years were reported as having a much higher prevalence of diabetes than US-born patients with TB in the same age group (figure 2), suggesting that the increasing diabetes prevalence worldwide could be affecting TB's epidemiology in the USA. Addressing that challenge will require coordination between the private sector, where case management of diabetes often resides, and the public health sector, which has been charged with the responsibility for controlling and eventually eliminating TB in the USA.

Acknowledgements We gratefully acknowledge the contributions and efforts of local and state health departments that report cases into the National Tuberculosis Surveillance System. We thank Kristen Renneker for her earlier unpublished analysis with 2009–2011 data and C Kay Smith for editorial services.

Contributors LRA conceived and executed the analysis. JSK provided analytic assistance. JSK and MBH reviewed interim results, provided interpretation, and suggested additional analyses. LRA created the first draft of the article, and MBH revised the article. All authors approved the final version.

Funding This is a publicly funded research by employees of the Centers for Disease Control and Prevention, Atlanta, Georgia.

Disclaimer The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement The National Tuberculosis Surveillance System operates under an Assurance of Confidentiality issued by the Centers for Disease Control and Prevention (CDC) under Sections 306 and 308(d) of the Public Health Service Act (42 USC 242k and 242m(d)). Data are reported voluntarily to CDC by state and local health departments on a case report form called the Report of Verified Case of Tuberculosis (OMB No. 0920-0026). The Assurance of Confidentiality prevents disclosure of any information that could be used to directly or indirectly identify patients. For more information, see the CDC/ATSDR Policy on Releasing and Sharing Data (at <http://www.cdc.gov/maso/Policy/ReleasingData.pdf>). A limited dataset is available at <http://wonder.cdc.gov/TB-v2013.html>. Researchers may apply to analyze additional data at CDC headquarters by contacting TBInfo@cdc.gov.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iD

Maryam B Haddad <http://orcid.org/0000-0001-6327-068X>

REFERENCES

- 1 Lönnroth K, Roglic G, Harries AD. Improving tuberculosis prevention and care through addressing the global diabetes epidemic: from evidence to policy and practice. *Lancet Diabetes Endocrinol* 2014;2:730–9.
- 2 Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. *Clin Infect Dis* 2016;63:e147–95.
- 3 Zafar MI, Chen L-L, Xiaofeng Y, et al. Impact of diabetes mellitus on radiological presentation of pulmonary tuberculosis in otherwise non-immunocompromised patients: a systematic review. *Curr Med Imaging Rev* 2019;15:543–54.
- 4 Jiménez-Corona ME, Cruz-Hervert LP, García-García L, et al. Association of diabetes and tuberculosis: impact on treatment and post-treatment outcomes. *Thorax* 2013;68:214–20.
- 5 Ma Y, Huang ML, Li T, et al. Role of diabetes mellitus on treatment effects in drug-susceptible initial pulmonary tuberculosis patients in China. *Biomed Environ Sci* 2017;30:671–5.
- 6 Baker MA, Harries AD, Jeon CY, et al. The impact of diabetes on tuberculosis treatment outcomes: a systematic review. *BMC Med* 2011;9:81.
- 7 Nguyen CH, Pascopella L, Barry PM. Association between diabetes mellitus and mortality among patients with tuberculosis in California, 2010–2014. *Int J Tuberc Lung Dis* 2018;22:1269–76.
- 8 Armstrong LR, Winston CA, Stewart B, et al. Changes in tuberculosis epidemiology, United States, 1993–2017. *Int J Tuberc Lung Dis* 2019;23:797–804.
- 9 Centers for Disease Control and Prevention (CDC). *CDC tuberculosis surveillance data training — report of verified case of tuberculosis*. Atlanta, GA: US Department of Health and Human Services, CDC, 2009. <https://www.cdc.gov/tb/programs/rvct/default.htm>
- 10 Li C, Ford ES, Zhao G, et al. Age adjustment of diabetes prevalence: use of 2010 U.S. Census data. *J Diabetes* 2014;6:451–61.
- 11 Centers for Disease Control and Prevention (CDC). *Diabetes report card 2017*. Atlanta, GA: US Department of Health and Human Services, CDC, 2018. <https://www.cdc.gov/diabetes/library/reports/reportcard.html>
- 12 Magee MJ, Kempker RR, Kipiani M, et al. Diabetes mellitus is associated with cavities, smear grade, and multidrug-resistant tuberculosis in Georgia. *Int J Tuberc Lung Dis* 2015;19:685–92.
- 13 Harries AD, Kumar AMV, Satyanarayana S, et al. Communicable and non-communicable diseases: connections, synergies and benefits of integrating care. *Public Health Action* 2015;5:156–7.
- 14 Magee MJ, Salindri AD, Gujral UP, et al. Convergence of non-communicable diseases and tuberculosis: a two-way street? *Int J Tuberc Lung Dis* 2018;22:1258–68.
- 15 Ronacher K, van Crevel R, Critchley JA, et al. Defining a research agenda to address the converging epidemics of tuberculosis and diabetes: Part 2: underlying biologic mechanisms. *Chest* 2017;152:174–80.
- 16 Menon S, Rossi R, Nshimyumukiza L, et al. Convergence of a diabetes mellitus, protein energy malnutrition, and TB epidemic: the neglected elderly population. *BMC Infect Dis* 2016;16:361.
- 17 Barron MM, Shaw KM, Bullard KM, et al. Diabetes is associated with increased prevalence of latent tuberculosis infection: findings from the National Health and Nutrition Examination Survey, 2011–2012. *Diabetes Res Clin Pract* 2018;139:366–79.
- 18 Miramontes R, Hill AN, Yelk Woodruff RS, et al. Tuberculosis infection in the United States: prevalence estimates from the National Health and Nutrition Examination Survey, 2011–2012. *PLoS One* 2015;10:e0140881.
- 19 US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, et al. Screening for latent tuberculosis infection in adults: US Preventive Services Task Force recommendation statement. *JAMA* 2016;316:962–9.
- 20 Cho NH, Shaw JE, Karuranga S, et al. IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. *Diabetes Res Clin Pract* 2018;138:271–81.